Acadia Realty Trust Stock Soars 13.86% on Institutional Buying

Generated by AI AgentAinvest Movers Radar
Tuesday, Apr 8, 2025 4:51 am ET1min read
AKR--

On April 8, 2025, Acadia Realty Trust's stock surged by 13.86% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Acadia Realty Trust has seen a mix of positive and negative developments recently. The company's stock has been the subject of various analyst ratings and price targets. According to four analysts, the average rating for AKRAKR-- stock is "Buy," with a 12-month stock price forecast of $22.0, indicating a potential increase of 21.48% from the latest price. Additionally, the company's free cash flow for Q4 2024 was $0.69, and its operating cash flow was $0.25 for the 2024 fiscal year.

Institutional investors have been actively adjusting their holdings in Acadia Realty TrustAKR--. Pictet Asset Management Holding SA increased its stake by 36.9% in the fourth quarter, while Smartleaf Asset Management LLC lifted its stake by 91.3%. Other institutional investors, including USA Financial Formulas, KBC Group NV, Xponance Inc., and Longboard Asset Management LP, have also made significant changes to their holdings. Currently, 97.65% of the stock is owned by hedge funds and other institutional investors.

Acadia Realty Trust recently declared a quarterly dividend of $0.20 per share, payable on April 15, 2025. This represents an annualized dividend of $0.80 and a yield of 4.37%, marking an increase from the previous quarterly dividend of $0.19. The company's dividend payout ratio is currently at 444.44%.

Insider activity has also been noted, with EVP Jason Blacksberg selling 30,000 shares of the company's stock at an average price of $22.81 on March 6, 2025. Company insiders own 2.83% of the company's stock.

Knowing stock market today at a glance

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet